Trial Profile
Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy. Observational, Descriptive, Open-label, Multi-centric, Non-randomized Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Vigabatrin (Primary) ; Vigabatrin
- Indications Infantile spasms; Partial epilepsies
- Focus Therapeutic Use
- Acronyms SoluWest
- Sponsors ORPHELIA Pharma; Targeon
- 23 Apr 2018 Status changed from recruiting to completed.
- 27 Feb 2018 According to the ORPHELIA Pharma media release, results of this study were presented at the congress of the French Pediatric Neurology Society.
- 09 Oct 2015 According to the ORPHELIA Pharma media release, TargeOn changed its name to ORPHELIA Pharma